PIONEER: A Phase I Study of Olaparib in Combination with Chemo-radiation in Locally Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 May 2017
At a glance
- Drugs Olaparib (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms PIONEER
- 18 Sep 2015 Accrual to date is 2% as reported by United kingdom Clinical Research Network record.
- 20 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.
- 18 Mar 2015 New trial record